Key facts
- It has raised $93.1M.
- Notable investors include Novo Holdings, Denmark's Export and Investment Fund, Nordic Mentor Network For Entrepreneurship, SR One Capital Management, Versant Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Antag Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Antag Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Antag Therapeutics
Operator of a biotechnology company intended to focus on developing metabolic and anti-obesity therapeutic drugs. The company specializes in the creation of peptide-based gastric inhibitory polypeptide receptor antagonists to monitor dietary-related metabolic diseases through infusion, enabling the healthcare industry to decrease blood flow and lipid uptake in adipose tissue efficiently.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2016
- Employees
- 20
- Website
- antagtx.com/
- Ownership
- Privately Held (backing)
Antag Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Antag Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Antag Therapeutics in its N-PORT filings yet. We sweep new filings monthly.